Вроджена гіперплазія надниркових залоз внаслідок дефіциту 21-гідроксилази. Клінічні практичні настанови Ендокринологічного Товариства. Частина 1
DOI:
https://doi.org/10.1210/jc.2018-01865Ключові слова:
-Анотація
Мета: оновити клінічні практичні настанови щодо вродженої гіперплазії надниркових залоз унаслідок дефіциту 21-гідроксилази, що були опубліковані Ендокринним Товариством у 2010 році.
Висновки: представлені оновлені рекомендації з найкращої практики щодо клінічного управління вродженою гіперплазією надниркових залоз на основі опублікованих даних та експертної думки з додатковими міркуваннями щодо безпеки пацієнтів, якості життя, витрат та використання (J. Clin. Endocrinol. Metab. 103: 1—46, 2018).
Посилання
Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, Meyer-Bahlburg HFL, Miller WL, Montori VM, Oberfield SE, Ritzen M, White PC. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J ClinEndocrinolMetab. 2010;95(9):4133-4160.
Gruñieiro-Papendieck L, Chiesa A, Mendez V, Prieto L. Neonatal screening for congenital adrenal hyperplasia: experience and results in Argentina. J PediatrEndocrinolMetab. 2008;21(1):73-78.
Shetty VB, Bower C, Jones TW, Lewis BD, Davis EA. Ethnic and gender differences in rates of congenital adrenal hyperplasia in Western Australia over a 21 year period. J Paediatr Child Health. 2012;48(11):1029-1032.
Gleeson HK, Wiley V, Wilcken B, Elliott E, Cowell C, Thonsett M, Byrne G, Ambler G. Two-year pilot study of newborn screening forcongenital adrenal hyperplasiain New South Walescompared with nationwide case surveillance in Australia. J Paediatr Child Health. 2008;44(10):554-559.
Nascimento ML, Cristiano AN, Campos T, Ohira M, Cechine lE, Simoni G, Lee J, Linhares RM, Silva PC. Ten-year evaluation of a neonatal screening program for congenital adrenal hyperplasia. Arq Bras EndocrinolMetabol. 2014;58(7):765-771.
Silveira EL, Elnecave RH, dos Santos EP, Moura V, Pinto EM, Van der Linden Nader I, Mendonca BB, Bachega TA. Molecular analysis of CYP21A2 can optimize the follow-up of positive results in newborn screening for congenital adrenal hyperplasia. Clin Genet. 2009;76(6):503-510.
Pezzuti IL, Barra CB, Mantovani RM, Januário JN, Silva IN. A three-year follow-up of congenital adrenal hyperplasia newborn screening. J Pediatr (Rio J). 2014;90(3):300-307.
Kopacek C, de Castro SM, Prado MJ, da Silva CM, Beltr~ao LA, Spritzer PM. Neonatal screening for congenital adrenal hyperplasiainSouthernBrazil:apopulationbasedstudywith108,409 infants. BMC Pediatr. 2017;17(1):22.
Zhong K, Wang W, He F, Wang Z. The status of neonatal screening in China, 2013. J Med Screen. 2016;23(2):59-61.
Dumic K, Krnic N, Skrabic V, Stipancic G, Cvijovic K, Kusec V, Stingl K. Classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency in Croatia between 1995 and 2006. Horm Res. 2009;72(5):310-314.
González EC, Carvajal F, Fr´ometa A, Arteaga AL, Castells EM, Espinosa T, Coto R, Pérez PL, Tejeda Y, Del R´ ıo L, Segura MT, Almenares P, Robaina R, Fernández JL. Newborn screening for congenital adrenal hyperplasia in Cuba: six years of experience. Clin Chim Acta. 2013;421:73-78.
Votava F, Novotna D, Kracmar P, Vinohradska H, StahlovaHrabincova E, Vrzalova Z, Neumann D, Malikova J, Lebl J, Matern D. Lessons learned from 5 years of newborn screening for congenital adrenal hyperplasia in the Czech Republic: 17-hydroxyprogesterone, genotypes, and screening performance. Eur J Pediatr. 2012;171(6):935-940.
Coulm B, Coste J, Tardy V, Ecosse E, Roussey M, Morel Y, Carel JC; DHCSF Study Group. Efficiency of neonatal screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency in children born in mainland France between 1996 and 2003. Arch PediatrAdolesc Med. 2012;166(2):113-120.
Odenwald B, Dörr HG, Bonfig W, Schmidt H, Fingerhut R, Wildner M, Nennstiel-Ratzel U. Classic congenital adrenal hyperplasia due to 21-hydroxylase-deficiency: 13 years of neonatal screening and follow-up in Bavaria. KlinPadiatr. 2015;227(5):278-283.
Kaur G, Thakur K, Kataria S, Singh TR, Chavan BS, Kaur G, AtwalR.Currentand future perspective of new born screening:an Indian scenario. J PediatrEndocrinolMetab. 2016;29(1):5-13.
Morikawa S, Nakamura A, Fujikura K, Fukushi M, Hotsubo T, Miyata J, Ishizu K, Tajima T. Results from 28 years of newborn screening for congenital adrenal hyperplasia in Sapporo. Clin Pediatr Endocrinol. 2014;23(2):35-43.
Tsuji A, Konishi K, Hasegawa S, Anazawa A, Onishi T, Ono M, Morio T, Kitagawa T, Kashimada K. Newborn screening for congenital adrenal hyperplasia in Tokyo, Japan from 1989 to 2013: a retrospective population-based study. BMC Pediatr. 2015;15(1):209.
Heather NL, Seneviratne SN, Webster D, Derraik JG, Jefferies C, Carl lJ, Jiang Y, Cutfield WS, Hofman PL. Newborn screening for congenital adrenal hyperplasia in New Zealand, 1994-2013. J Clin Endocrinol Metab. 2015;100(3):1002-1008.
Gidlöf S, Wedell A, Guthenberg C, von Döbeln U, Nordenström A. Nationwide neonatal screening for congenital adrenal hyperplasia in Sweden: a 26-year longitudinal prospective population based study. JAMA Pediatr. 2014;168(6):567-574.
Khalid JM, Oerton JM, Dezateux C, Hindmarsh PC, Kelnar CJ, Knowles RL. Incidence and clinical features of congenital adrenal hyperplasia in Great Britain. Arch Dis Child. 2012;97(2):101-106.
Al Hosani H, Salah M, Osman HM, Farag HM, El-Assiouty L, Saade D, Hertecant J. Expanding the comprehensive national neonatal screening programme in the United Arab Emirates from 1995 to 2011. East Mediterr Health J. 2014;20(1):17-23.
Larrandaburu M, Matte U, Noble A, Olivera Z, Sanseverino MT, Nacul L, Schuler-Faccini L. Ethics, genetics and public policies in Uruguay: newborn and infant screening as a paradigm. J Community Genet. 2015;6(3):241-249.
Van der Kamp HJ, Wit JM. Neonatal screening for congenital adrenal hyperplasia. Eur J Endocrinol. 2004;151(Suppl 3):U71-U75.
White PC, New MI, Dupont B. HLA-linked congenital adrenal hyperplasia results from a defective gene encoding a cytochrome P-450 specific for steroid 21-hydroxylation. ProcNatlAcadSci USA. 1984;81(23):7505-7509.
Krone N, Dhir V, Ivison HE, Arlt W. Congenital adrenal hyperplasia and P450 oxidoreductase deficiency. Clin Endocrinol (Oxf). 2007;66(2):162-172.
Kamrath C, Hochberg Z, Hartmann MF, Remer T, Wudy SA. Increased activation of the alternative “backdoor” pathway in patients with 21-hydroxylase deficiency: evidence from urinary steroid hormone analysis. J Clin Endocrinol Metab. 2012;97(3):E367-E375.
White PC, Speiser PW.Congenital adrenal hyperplasia dueto 21hydroxylase deficiency. Endocr Rev. 2000;21(3):245-291.
National Newborn Screening and Global Resource Center. Newborn Screening Reports and Publications. Incidence reports: 2006. Available at: genes-r-us.uthscsa.edu/newborn_reports. Accessed 28 August 2017.
Kohn B, Levine LS, Pollack MS, Pang S, Lorenzen F, Levy D, Lerner AJ, Rondanini GF, Dupont B, New MI. Late-onset steroid 21-hydroxylase deficiency: a variant of classical congenital adrenal hyperplasia. J Clin Endocrinol Metab.1982;55(5):817-827.
Speiser PW, Dupont BO, Rubinstein P, Piazza A, Kastelan A, New MI. High frequency of nonclassical steroid 21-hydroxylase deficiency. ObstetGynecolSurv. 1986;41(4):244-245.
Hannah-Shmouni F, Morissette R, Sinaii N, Elman M, Prezant TR, Chen W, Pulver A, Merke DP. Revisiting the prevalence of nonclassic congenital adrenal hyperplasia in US Ashkenazi Jews and Caucasians. Genet Med. 2017;19(11):1276-1279.
Yang Z, Mendoza AR, Welch TR, Zipf WB, Yu CY. Modular variations ofthe human major histocompati bility complex class III genes for serine/threonine kinase RP, complement component C4, steroid 21-hydroxylase CYP21, and tenascin TNX (the RCCX module). A mechanism for genedeletions and disease associations. J Biol Chem. 1999;274(17):12147-12156.
The Human Gene Mutation Database. Available at: www.hgmd. cf.ac.uk/ac/index.php. Accessed July 27, 2018.
Krone N, Braun A, Roscher AA, Knorr D, Schwarz HP. Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany. J Clin Endocrinol Metab. 2000;85(3):1059-1065.
Speiser PW, Dupont J, Zhu D, Serrat J, Buegeleisen M, Tusie-Luna MT, Lesser M, New MI, White PC. Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest. 1992;90(2):584-595.
Simonetti L, Bruque CD, Fernández CS, Benavides-Mori B, Delea M, Kolomenski JE, Espeche LD, Buzzalino ND, Nadra AD, Dain L. CYP21A2 mutation update: Comprehensive analysis of databases and published genetic variants. Hum Mutat. 2018;39(1):5-22.
Miller WL, Merke DP. Tenascin-X, congenital adrenal hyperplasia and the CAH-X syndrome. Horm Res Paediatr. 2018; 89(5):352-361.
Tusie-Luna MT, Traktman P, White PC. Determination of functional effects of mutationsin the steroid 21-hydroxylase gene (CYP21) using recombinant vaccinia virus. J Biol Chem. 1990; 265(34):20916-20922.
Blanché H, Vexiau P, Clauin S, Le Gall I, Fiet J, Mornet E, Dausset J, Bellanné-Chantelot C. Exhaustive screening of the 21-hydroxylase gene in a population of hyperandrogenic women. Hum Genet. 1997;101(1):56-60.
Deneux C, Tardy V, Dib A, Mornet E, Billaud L, Charron D, Morel Y, Kuttenn F. Phenotype-genotype correlation in 56 women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2001;86(1):207-213.
Tamhane SU, Rodriguez-Gutierrez R, Iqbal AM, Prokop L, Bancos I, Speiser PW, Murad MH. Cardiovascular and metabolic out comesin congenital adrenal hyperplasia: a systematic review and metaanalysis. J Clin Endocrinol Metab. 2018;103(11):4097—4103.
Almasri J, Zaiem F, Rodriguez-Gutierrez R, Tamhane SU, Iqbal AM, Prokop LJ, Speiser PW, Baskin LS, Bancos I, Murad MH. Genital reconstructive surgery in females with congenital adrenal hyperplasia: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2018;103(11):4089—4096.
Pang S, Shook MK. Current status of neonatal screening for congenital adrenal hyperplasia. CurrOpinPediatr. 1997;9(4):419-423.
Therrell BL. Newborn screening for congenital adrenal hyperplasia. Endocrinol Metab Clin North Am. 2001;30(1):15-30.
Balsamo A, Cacciari E, Piazzi S, Cassio A, Bozza D, Pirazzoli P, Zappulla F. Congenital adrenal hyperplasia: neonatal mass screening compared with clinical diagnosis only in the Emilia Romagna region of Italy,1980-1995.Pediatrics.1996;98(3Pt1):362-367.
Brosnan PG, Brosnan CA, Kemp SF, Domek DB, Jelley DH, Blackett PR, Riley WJ. Effect of new born screening for congenital adrenal hyperplasia. Arch PediatrAdolesc Med. 1999;153(12):1272-1278.
Therrell BL Jr, Berenbaum SA, Manter-Kapanke V, Simmank J, Korman K, Prentice L, Gonzalez J, Gunn S. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics. 1998;101(4 Pt 1):583-590.
Thilén A, Nordenström A, Hagenfeldt L, von Döbeln U, Guthenberg C, Larsson A. Benefits of neonatal screening for congenital adrenal hyperplasia (21-hydroxylase deficiency) in Sweden. Pediatrics. 1998;101(4):E11.
Strnadová KA, Votava F, Lebl J, Mühl A, Item C, Bodamer OA, Torresani T, Bouˇska I, Waldhauser F, Sperl W. Prevalence of congenital adrenal hyperplasia among sudden infant death in the Czech Republic and Austria. Eur J Pediatr. 2007;166(1):1-4.
Hird BE, Tetlow L, Tobi S, Patel L, Clayton PE. Noevidence of an increase in early infant mortality from congenital adrenal hyperplasia in the absence of screening. Arch Dis Child. 2014;99(2):158-164.
Lebovitz RM, Pauli RM, Laxova R. Delayed diagnosis in congenital adrenal hyperplasia. Need for newborn screening. Am J Dis Child. 1984;138(6):571-573.
Nordenström A, Ahmed S, Jones J, Coleman M, Price DA, Clayton PE, Hall CM. Female preponderance in congenital adrenal hyperplasia due to CYP21 deficiency in England: implications for neonatal screening. Horm Res. 2005;63(1):22-28.
Thompson R, Seargeant L, Winter JS. Screening for congenital adrenal hyperplasia: distribution of 17a-hydroxyprogesterone concentrations in neonatal bloodspotspecimens. J Pediatr.1989;114(3):400-404.
Gidlöf S, Falhammar H, Thilén A, von Döbeln U, Ritzén M, Wedell A, Nordenström A. One hundred years of congenital adrenal hyperplasia in Sweden: a retrospective, population-based cohort study. Lancet Diabetes Endocrinol. 2013;1(1):35-42.
Watson MS, Mann MY, Lloyd-Puryear MA, Rinaldo P, Howell RR, eds. Newborn screening: toward a uniform screening panel and system [Main report]. Genet Med. 2006;8(Suppl 1):12S-252S.
Grosse SD, Van Vliet G. How many deaths can be prevented by new born screening for congenital adrenal hyperplasia? Horm Res. 2007;67(6):284-291.
VanderKamp HJ, Noordam K, Elvers B, Van Baarle M, Otten BJ, Verkerk PH. Newborn screening for congenital adrenal hyperplasia in the Netherlands. Pediatrics. 2001;108(6):1320-1324.
Nass R, Baker S. Learning disabilities in children with congenital adrenal hyperplasia. J Child Neurol. 1991;6(4):306-312.
Carroll AE, Downs SM. Comprehensive cost-utility analysis of newborn screening strategies. Pediatrics. 2006;117(5 Pt 2):S287-S295.
Yoo BK, Grosse SD. Thecost effectiveness of screening newborns for congenital adrenal hyperplasia. Public Health Genomics. 2009;12(2):67-72.
Chan CL, Mc Fann K, Taylor L, Wright D, Zeitler PS, Barker JM. Congenital adrenal hyperplasia and the second newborn screen. J Pediatr. 2013;163(1):109-113.e1.
Gonzalez RR, Mäentausta O, Solyom J, Vihko R. Directsolid-phase time-resolved fluoroimmunoassay of 17a-hydroxyprogesterone in serum and dried bloodspots on filter paper. Clin Chem.1990;36(9):1667-1672.
Pang S, Hotchkiss J, Drash AL, Levine LS, New MI. Microfilter paper method for 17a-hydroxyprogesterone radioimmunoassay: its application for rapid screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1977;45(5):1003-1008.
Varness TS, Allen DB, Hoffman GL. Newborn screening for congenital adrenal hyperplasia has reduced sensitivity in girls. J Pediatr. 2005;147(4):493-498.
Allen DB, Hoffman GL, Fitzpatrick P, Laessig R, Maby S, Slyper A. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels. J Pediatr. 1997;130(1):128-133.
Olgemöller B, Roscher AA, Liebl B, Fingerhut R. Screening for congenital adrenal hyperplasia: adjustmentof17-hydroxyprogesteronecutoff values to both age and birth weight markedly improves the predictive value. J Clin Endocrinol Metab. 2003;88(12):5790-5794.
Sarafoglou K, Gaviglio A, Hietala A, Frogner G, Banks K, McCann M, Thomas W. Comparison of newborn screening protocols for congenital adrenal hyperplasia in preterm infants. J Pediatr. 2014;164(5):1136-1140.
Sarafoglou K, Banks K, Gaviglio A, Hietala A, McCann M, Thomas W. Comparison of one-tier and two-tier newborn screening metrics for congenital adrenal hyperplasia. Pediatrics. 2012;130(5):e1261-e1268.
Hayashi GY, Carvalho DF, de Miranda MC, Faure C, Vallejos C, Brito VN, Rodrigues AS, Madureira G, Mendonca BB, Bachega TA. Neonatal 17-hydroxyprogesterone levels adjusted according to age at sample collection and birthweight improve the efficacy of congenital adrenal hyperplasia newborn screening. ClinEndocrinol (Oxf). 2017;86(4):480-487.
Held PK, Shapira SK, Hinton CF, Jones E, Hannon WH, Ojodu J. Congenital adrenal hyperplasia cases identified by newborn screening in one- and two-screen states. Mol Genet Metab. 2015;116(3):133-138.
Van der Kamp HJ, Oudshoorn CGM, Elvers BH, Van Baarle M,Otten BJ, Wit JM, Verkerk PH. Cutoff levels of 17-a-hydroxyprogesterone in neonatal screening for congenital adrenal hyperplasia should be based on gestational age rather than on birth weight. J Clin Endocrinol Metab. 2005;90(7):3904-3907.
Nomura S. Immature adrenal steroidogenesis in preterm infants. Early Hum Dev. 1997;49(3):225-233.
Wong T, Shackleton CHL, Covey TR, Ellis G. Identification of the steroids in neonatal plasma that interfere with 17 a-hydroxyprogesterone radioimmunoas says. Clin Chem.1992;38(9):1830-1837.
Al Saedi S, Dean H, Dent W, Cronin C. Reference ranges for serum cortisol and 17-hydroxyprogesterone levels in preterm infants. J Pediatr. 1995;126(6):985-987.
Gatelais F, Berthelot J, Beringue F, Descamps P, Bonneau D, Limal J-M, Coutant R. Effect of single and multiple courses of prenatal corticosteroidson 17-hydroxyprogesterone levels: implicationfor neonatal screening of congenital adrenal hyperplasia. Pediatr Res. 2004;56(5):701-705.
King JL, Naber JM, Hopkin RJ, Repaske DR, Bailey L, Leslie ND. Antenatal corticosteroids and newborn screening for congenital adrenal hyperplasia. Arch PediatrAdolesc Med. 2001;155(9):1038-1042.
White PC. Neonatal screening for congenital adrenalh yperplasia. Nat Rev Endocrinol. 2009;5(9):490-498.
Lacey JM, Minutti CZ, Magera MJ, Tauscher AL, Casetta B, McCann M, Lymp J, Hahn SH, Rinaldo P, Matern D. Improved specificity of newborn screening for congenital adrenal hyperplasia by second-tier steroid profiling using tandem mass spectrometry. Clin Chem. 2004;50(3):621-625.
Rauh M, Gröschl M, Rascher W, Dörr HG. Automated, fast and sensitive quantification of 17a-hydroxy-progesterone, androstenedione and testosterone by tandem mass spectrometry with online extraction. Steroids. 2006;71(6):450-458.
Janzen N, Peter M, Sander S, Steuerwald U, Terhardt M, Holtkamp U, Sander J. New born screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatographytandem mass spectrometry. J ClinEndocrinolMetab. 2007;92(7):2581-2589.
Minutti CZ, Lacey JM, Magera MJ, Hahn SH, McCann M, Schulze A, Cheillan D, Dorche C, Chace DH, Lymp JF, Zimmerman D, Rinaldo P, Matern D. Steroid profiling bytandem mass spectrometry improves the positive predictive value of newborn screening for congenital adrenal hyperplasia. J ClinEndocrinolMetab. 2004;89(8):3687-3693.
Matern D, Tortorelli S, Oglesbee D, Gavrilov D, Rinaldo P. Reduction of the false-positive rate in newborn screening by implementation of MS/MS-based second-tier tests: the Mayo Clinic experience (2004-2007). J Inherit Metab Dis. 2007;30(4): 585-592.
chwarz E, Liu A, Randall H, Haslip C, Keune F, Murray M, Longo N, Pasquali M. Use of steroid profiling by UPLC-MS/MS as a second tier test in newborn screening for congenital adrenal hyperplasia: the Utah experience. Pediatr Res. 2009;66(2):230-235.
Seo JY, Park H-D, Kim JW, Oh HJ, Yang JS, Chang YS, Park WS, Lee S-Y. Steroid profiling for congenital adrenal hyperplasia by tandem mass spectrometry as a second-tier test reduces follow-up burdensinatertiary care hospital: aretrospective and prospective evaluation. J Perinat Med. 2014;42(1):121-127.
DeJes´us VR, Simms DA, Schiffer J, Kennedy M, Mei JV, Hannon WH. Pilot proficiency testing study for second tier congenital adrenal hyperplasia newborn screening. ClinChimActa. 2010;411(21-22):1684-1687.
Kamrath C, Hartmann MF, BoettcherC, ZimmerK-P, WudySA. Diagnosis of 21-hydroxylase deficiency by urinary metabolite ratios using gas chromatography-mass spectrometry analysis: reference values for neonates and infants. J Steroid BiochemMol Biol. 2016;156:10-16.
Yang YP, Corley N, Garcia-Heras J. Reverse dot-blot hybridization as an improved tool for the molecular diagnosis of point mutations in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency. MolDiagn. 2001;6(3):193-199.
Fitness J, Dixit N, Webster D, Torresani T, Pergolizzi R, Speiser PW, Day DJ. Genotyping of CYP21, linked chromosome 6p markers, and a sex-specific gene in neonatal screening for congenital adrenal hyperplasia.J Clin Endocrinol Metab.1999;84(3):960-966.
Sorensen KM, Andersen PS, Larsen LA, Schwartz M, Schouten JP, Nygren AO. Multiplex ligation-dependent probe amplification technique for copy number analysis on small amounts of DNA material. Anal Chem. 2008;80(23):9363-9368.
KöselS, Burggraf S, FingerhutR,Dörr HG, RoscherAA, Olgemöller B. Rapid second-tier molecular genetic analysis for congenital adrenal hyperplasia attributable to steroid 21-hydroxylase deficiency. Clin Chem. 2005;51(2):298-304.
Olney RC, Mougey EB, Wang J, Shulman DI, Sylvester JE. Using real-time, quantitative PCR for rapid genotyping of the steroid 21-hydroxylase gene in a north Florida population. J Clin Endocrinol Metab. 2002;87(2):735-741.
Nordenström A, Thilén A, Hagenfeldt L, Larsson A, Wedell A. Genotyping is a valuable diagnostic complement to neonatal screening for congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab. 1999;84(5):1505-1509.
Riepe FG, Krone N, Viemann M, Partsch C-J, Sippell WG. Management of congenital adrenal hyperplasia: results of the ESPE questionnaire. Horm Res. 2002;58(4):196-205.
Németh S, Riedl S, Kriegsh¨auser G, Baumgartner-Parzer S, Concolino P, Neocleous V, Phylactou LA, Borucka-Mankiewicz M, Onay H, Tukun A, Oberkanins C. Reverse-hybridization assay for rapid detection of common CYP21A2 mutations in dried blood spots from newborns with elevated 17-OH progesterone. ClinChimActa. 2012;414:211-214.
